281 related articles for article (PubMed ID: 6890839)
1. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
2. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
[TBL] [Abstract][Full Text] [Related]
3. [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
Rietbrock N; Knoll J; Merz PG; Menke G
Dtsch Med Wochenschr; 1985 Nov; 110(47):1821-5. PubMed ID: 3905327
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud LF; Doyle E; Taylor T; Darragh A; Lambe RF
Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):514-8. PubMed ID: 6642789
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations].
Chasseaud LF; Taylor T; Major RM; Taylor IW; Luckow V; Darragh A; Lambe RF
Arzneimittelforschung; 1983; 33(9):1298-301. PubMed ID: 6685511
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen H; Leitold M; Wildfeuer A
Arzneimittelforschung; 1988 Sep; 38(9):1336-41. PubMed ID: 3223973
[TBL] [Abstract][Full Text] [Related]
7. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
[TBL] [Abstract][Full Text] [Related]
8. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
Neugebauer G; Akpan W; Stemmle B; Jaeger H; Mosberg H; Lutz D
Int J Clin Pharmacol Ther Toxicol; 1989 Jan; 27(1):34-8. PubMed ID: 2744904
[TBL] [Abstract][Full Text] [Related]
9. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
Laufen H; Aumann M; Leitold M
Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers.
Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E
Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439
[TBL] [Abstract][Full Text] [Related]
11. [Concentration-time profile of isosorbide dinitrate and its metabolites in plasma following percutaneous resorption of a transdermal therapeutic system].
Menke G; Schnellhammer R; Rietbrock N
Arzneimittelforschung; 1987 Nov; 37(11):1301-3. PubMed ID: 3440041
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Skutta T; Böttcher B; Brandt L
Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
Keller-Stanislawski B; Marschner JP; Rietbrock N
Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
[TBL] [Abstract][Full Text] [Related]
14. [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
Taylor T; Major RM; Leaf FC; Cook SC; Chasseaud LF; Darragh A; Lambe RF
Arzneimittelforschung; 1984; 34(11):1584-7. PubMed ID: 6543135
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Smith D; Aldrich W; Dey M; Enever R; Warner R; Weierstall R
Drug Metab Dispos; 1990; 18(4):429-34. PubMed ID: 1976063
[TBL] [Abstract][Full Text] [Related]
16. [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
Muck B; Bonn R; Rietbrock N
Arzneimittelforschung; 1989 Oct; 39(10):1274-6. PubMed ID: 2610720
[TBL] [Abstract][Full Text] [Related]
17. Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
Johnson KI; Gladigau V; Schnelle K
Arzneimittelforschung; 1981; 31(6):1026-9. PubMed ID: 7196234
[TBL] [Abstract][Full Text] [Related]
18. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
Kogi K; Tanaka O; Kimura T; Saito T
Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
[TBL] [Abstract][Full Text] [Related]
19. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
Sata H; Inoue K; Nii T; Kuroda T
Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
[TBL] [Abstract][Full Text] [Related]
20. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
